Today, physicians diagnose AD primarily through subjective behavioral examinations and must monitor patients for three or more years of deterioration before a diagnosis can be made. In contrast, Orasi is developing a test that will help provide a definitive diagnosis in as little as one month. This will enable physicians, patients, and caregivers to more quickly implement treatment options, and make critical lifestyle decisions sooner.

Orasi is developing a diagnostic test that is highly sensitive, objective, noninvasive, and patient-friendly that will detect the unique disruptions in the electrical activity of the brain caused by AD to aid a physician in the early diagnosis and initiation of treatment. Orasi’s technology utilizes a fully automated and proprietary platform to collect and analyze MEG scans and will deliver a diagnostic report to a physician. Unlike other diagnostics, Orasi’s test will not require the use of injected radiomarkers, subjective cognitive evaluation, or the invasive draw of cerebrospinal fluid (CSF).

Orasi’s platform will provide a fast and easy testing procedure that is very patient-friendly. Patients are easily and comfortably seated under the MEG instrument, and no part of the instrument is in contact with their body. A scan, which takes less than 5 minutes, with hundreds of sensors around the head, generates over 100,000 separate data features. The entire process requires about 10 minutes of patient and technician time.

*Orasi Index is not currently FDA approved